PHK
VERV

Point72 Hong Kong’s Verve Therapeutics VERV Stock Holding History

Point72 Hong Kong’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,253
Closed -$120K – 2439
2022
Q1 		$120K Buy
+5,253
New +$150K ﹤0.01% 1105
2021
Q3 		– Sell
-5,700
Closed -$343K – 2462
2021
Q2 		$343K Buy
+5,700
New +$237K 0.01% 1016

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Point72 Hong Kong's VERV Position: Q2 2022 in Review

Point72 Hong Kong sold out of Verve Therapeutics (VERV) in Q2 2022, closing a stake of 5,253 shares — an estimated $120K sold.

Point72 Hong Kong first reported a position in VERV in Q2 2021 and held it in 2 quarters. The position peaked at $343K in Q2 2021. 101 funds tracked by Wall St. Rank hold VERV as of Q2 2022.

  • Point72 Hong Kong reported no remaining Verve Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 5,253 Verve Therapeutics shares in Q2 2022, an estimated $120K.
  • Point72 Hong Kong first reported a position in Verve Therapeutics in Q2 2021 and held it in 2 quarters.
  • Point72 Hong Kong's Verve Therapeutics position peaked at $343K in Q2 2021.
  • 101 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.